- Public Comps
- Racura Oncology
Racura Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Racura Oncology and similar public comparables like Amarin Corp, CytoDyn, Bicycle Therapeutics, Abclon and more.
Racura Oncology Overview
About Racura Oncology
Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.
Founded
2011
HQ

Employees
N/A
Website
Financials (FY)
EV
$277M
Valuation Multiples
Start free trialRacura Oncology Financials
Revenue (LTM)
Racura Oncology P&L
In the most recent fiscal year, Racura Oncology reported revenue of - and net income of -.
Financial data powered by Morningstar, Inc.
Racura Oncology Stock Performance
Racura Oncology has current market cap of $292M, and enterprise value of $277M.
Market Cap Evolution
Racura Oncology's stock price is $1.49.
Racura Oncology share price decreased by 2.6% in the last 30 days, and increased by 86.3% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $277M | $292M | -0.2% | -2.6% | -20.0% | 86.3% | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRacura Oncology Valuation Multiples
Racura Oncology Financial Valuation Multiples
As of July 19, 2026, Racura Oncology has market cap of $292M and EV of $277M.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Racura Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Racura Oncology Margins & Growth Rates
Racura Oncology Margins
Racura Oncology Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Racura Oncology Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Racura Oncology Competitors
Racura Oncology competitors include Amarin Corp, CytoDyn, Bicycle Therapeutics, Abclon, Lineage Cell Therapeutics, Duopharma Biotech, Macrogenics, Neumora Therapeutics, Newron Pharmaceuticals and Egetis Therapeutics.
Most Racura Oncology public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| (0.0x) | (0.1x) | 0.3x | 0.3x | |||
| - | - | 35.2x | - | |||
| (3.4x) | (5.5x) | 1.2x | 1.2x | |||
| 85.5x | - | (24.7x) | - | |||
| 16.4x | 15.6x | (11.3x) | (7.6x) | |||
| 1.4x | 1.4x | 7.4x | 7.2x | |||
| 1.1x | 1.1x | (2.8x) | - | |||
| - | - | (0.9x) | (1.1x) | |||
This data is available for Pro users. Sign up to see all Racura Oncology competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Racura Oncology
| When was Racura Oncology founded? | Racura Oncology was founded in 2011. |
| Where is Racura Oncology headquartered? | Racura Oncology is headquartered in Australia. |
| Is Racura Oncology publicly listed? | Yes, Racura Oncology is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Racura Oncology? | Racura Oncology trades under RAC ticker. |
| When did Racura Oncology go public? | Racura Oncology went public in 2016. |
| Who are competitors of Racura Oncology? | Racura Oncology main competitors include Amarin Corp, CytoDyn, Bicycle Therapeutics, Abclon, Lineage Cell Therapeutics, Duopharma Biotech, Macrogenics, Neumora Therapeutics, Newron Pharmaceuticals, Egetis Therapeutics. |
| What is the current market cap of Racura Oncology? | Racura Oncology's current market cap is $292M. |
| Is Racura Oncology profitable? | No, Racura Oncology is not profitable. |
| How many companies Racura Oncology has acquired to date? | Racura Oncology hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Racura Oncology has invested to date? | Racura Oncology hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Racura Oncology
Lists including Racura Oncology
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




